These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27282742)

  • 1. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Yang DY; Selyutin O; Jiang Y; Rosenblum SB; Kim SH; Lavey BJ; Zhou G; Rizvi R; Shankar BB; Zeng Q; Chen L; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3800-5. PubMed ID: 27282742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Coburn CA; Nair AG; Wong M; Rosenblum SB; Zhou G; Dwyer MP; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Kim SH; Zeng Q; Selyutin O; Chen L; Masse F; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Lin M; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3414-20. PubMed ID: 27394665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.
    Yu W; Coburn CA; Yang DY; Meinke PT; Wong M; Rosenblum SB; Chen KX; Njoroge GF; Chen L; Dwyer MP; Jiang Y; Nair AG; Selyutin O; Tong L; Zeng Q; Zhong B; Ji T; Hu B; Agrawal S; Xia E; Zhai Y; Liu R; Kong R; Ingravallo P; Asante-Appiah E; Nomeir A; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3158-3162. PubMed ID: 27180013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent macrocyclic HCV NS5A inhibitors.
    Yu W; Vibulbhan B; Rosenblum SB; Martin GS; Vellekoop AS; Holst CL; Coburn CA; Wong M; Selyutin O; Ji T; Zhong B; Hu B; Chen L; Dwyer MP; Jiang Y; Nair AG; Tong L; Zeng Q; Agrawal S; Carr D; Rokosz L; Liu R; Curry S; McMonagle P; Ingravallo P; Lahser F; Asante-Appiah E; Fells J; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3793-9. PubMed ID: 27282743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
    Coburn CA; Meinke PT; Chang W; Fandozzi CM; Graham DJ; Hu B; Huang Q; Kargman S; Kozlowski J; Liu R; McCauley JA; Nomeir AA; Soll RM; Vacca JP; Wang D; Wu H; Zhong B; Olsen DB; Ludmerer SW
    ChemMedChem; 2013 Dec; 8(12):1930-40. PubMed ID: 24127258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.
    Tong L; Yu W; Coburn CA; Chen L; Selyutin O; Zeng Q; Dwyer MP; Nair AG; Shankar BB; Kim SH; Yang DY; Rosenblum SB; Ruck RT; Davies IW; Hu B; Zhong B; Hao J; Ji T; Zan S; Liu R; Agrawal S; Carr D; Curry S; McMonagle P; Bystol K; Lahser F; Ingravallo P; Chen S; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5354-5360. PubMed ID: 27680588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.
    Yu W; Zhou G; Coburn CA; Zeng Q; Tong L; Dwyer MP; Hu B; Zhong B; Hao J; Ji T; Zan S; Chen L; Mazzola R; Kim JH; Sha D; Selyutin O; Rosenblum SB; Lavey B; Nair AG; Heon Kim S; Keertikar KM; Rokosz L; Agrawal S; Liu R; Xia E; Zhai Y; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Oct; 26(19):4851-4856. PubMed ID: 27568086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
    Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.
    Amblard F; Zhang H; Zhou L; Shi J; Bobeck DR; Nettles JH; Chavre S; McBrayer TR; Tharnish P; Whitaker T; Coats SJ; Schinazi RF
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2031-4. PubMed ID: 23466233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and evaluation of novel tetracyclic benzofurans as palm site allosteric inhibitors of HCV NS5B polymerase.
    Liu H; Dai X; He S; Brockunier L; Marcantonio K; Ludmerer SW; Li F; Feng KI; Nargund RP; Palani A
    Bioorg Med Chem Lett; 2019 Dec; 29(24):126104. PubMed ID: 30389294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5731-5737. PubMed ID: 25453810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.
    Ivashchenko AA; Ivanenkov YA; Aladinskiy VA; Karapetian RN; Koryakova AG; Ryakhovskiy AA; Mitkin OD; Kravchenko DV; Savchuk NP; Zagribelnyy BA; Ivashchenko AV
    Bioorg Med Chem; 2020 Oct; 28(20):115716. PubMed ID: 33069072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
    Tong L; Yu W; Coburn CA; Meinke PT; Nair AG; Dwyer MP; Chen L; Selyutin O; Rosenblum SB; Jiang Y; Fells J; Hu B; Zhong B; Soll RM; Liu R; Agrawal S; Xia E; Zhai Y; Kong R; Ingravallo P; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Oct; 26(20):5132-5137. PubMed ID: 27634194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
    Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.
    St Laurent DR; Belema M; Gao M; Goodrich J; Kakarla R; Knipe JO; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle D; Qiu Y; Romine JL; Serrano-Wu MH; Sun JH; Valera L; Yang F; Yang X; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6063-6. PubMed ID: 22959243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.